These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 30990809)

  • 1. Genetic mutational status of genes regulating epigenetics: Role of the histone methyltransferase KMT2D in triple negative breast tumors.
    Morcillo-Garcia S; Noblejas-Lopez MDM; Nieto-Jimenez C; Perez-Peña J; Nuncia-Cantarero M; Győrffy B; Amir E; Pandiella A; Galan-Moya EM; Ocana A
    PLoS One; 2019; 14(4):e0209134. PubMed ID: 30990809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KMT2D-mediated H3K4me1 recruits YBX1 to facilitate triple-negative breast cancer progression through epigenetic activation of c-Myc.
    Yao B; Xing M; Zeng X; Zhang M; Zheng Q; Wang Z; Peng B; Qu S; Li L; Jin Y; Li H; Yuan H; Zhao Q; Ma C
    Clin Transl Med; 2024 Jul; 14(7):e1753. PubMed ID: 38967349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of the role of mutations in the KMT2D histone lysine methyltransferase in bladder cancer.
    Ding B; Yan L; Zhang Y; Wang Z; Zhang Y; Xia D; Ye Z; Xu H
    FEBS Open Bio; 2019 Apr; 9(4):693-706. PubMed ID: 30984543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone methyltransferase KMT2D sustains prostate carcinogenesis and metastasis via epigenetically activating LIFR and KLF4.
    Lv S; Ji L; Chen B; Liu S; Lei C; Liu X; Qi X; Wang Y; Lai-Han Leung E; Wang H; Zhang L; Yu X; Liu Z; Wei Q; Lu L
    Oncogene; 2018 Mar; 37(10):1354-1368. PubMed ID: 29269867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of Kmt2c or Kmt2d drives brain metastasis via KDM6A-dependent upregulation of MMP3.
    Seehawer M; Li Z; Nishida J; Foidart P; Reiter AH; Rojas-Jimenez E; Goyette MA; Yan P; Raval S; Munoz Gomez M; Cejas P; Long HW; Papanastasiou M; Polyak K
    Nat Cell Biol; 2024 Jul; 26(7):1165-1175. PubMed ID: 38926506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KMT2C and KMT2D aberrations in breast cancer.
    Tinsley E; Bredin P; Toomey S; Hennessy BT; Furney SJ
    Trends Cancer; 2024 Jun; 10(6):519-530. PubMed ID: 38453563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Small Cell Lung Cancer Exhibits Frequent Inactivating Mutations in the Histone Methyltransferase KMT2D/MLL2: CALGB 151111 (Alliance).
    Augert A; Zhang Q; Bates B; Cui M; Wang X; Wildey G; Dowlati A; MacPherson D
    J Thorac Oncol; 2017 Apr; 12(4):704-713. PubMed ID: 28007623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of histone demethylases and histone methyltransferases in triple-negative breast cancer: Epigenetic mnemonics.
    Mandumpala JJ; Baby S; Tom AA; Godugu C; Shankaraiah N
    Life Sci; 2022 Mar; 292():120321. PubMed ID: 35031259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KMT2D Mutation Is Associated With Poor Prognosis in Non-Small-Cell Lung Cancer.
    Ardeshir-Larijani F; Bhateja P; Lipka MB; Sharma N; Fu P; Dowlati A
    Clin Lung Cancer; 2018 Jul; 19(4):e489-e501. PubMed ID: 29627316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histone H3 lysine 4 methyltransferase KMT2D.
    Froimchuk E; Jang Y; Ge K
    Gene; 2017 Sep; 627():337-342. PubMed ID: 28669924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancer Reprogramming Confers Dependence on Glycolysis and IGF Signaling in KMT2D Mutant Melanoma.
    Maitituoheti M; Keung EZ; Tang M; Yan L; Alam H; Han G; Singh AK; Raman AT; Terranova C; Sarkar S; Orouji E; Amin SB; Sharma S; Williams M; Samant NS; Dhamdhere M; Zheng N; Shah T; Shah A; Axelrad JB; Anvar NE; Lin YH; Jiang S; Chang EQ; Ingram DR; Wang WL; Lazar A; Lee MG; Muller F; Wang L; Ying H; Rai K
    Cell Rep; 2020 Oct; 33(3):108293. PubMed ID: 33086062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Whole-exome sequencing defines the mutational landscape of pheochromocytoma and identifies KMT2D as a recurrently mutated gene.
    Juhlin CC; Stenman A; Haglund F; Clark VE; Brown TC; Baranoski J; Bilguvar K; Goh G; Welander J; Svahn F; Rubinstein JC; Caramuta S; Yasuno K; Günel M; Bäckdahl M; Gimm O; Söderkvist P; Prasad ML; Korah R; Lifton RP; Carling T
    Genes Chromosomes Cancer; 2015 Sep; 54(9):542-54. PubMed ID: 26032282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic silencing of CREB3L1 by DNA methylation is associated with high-grade metastatic breast cancers with poor prognosis and is prevalent in triple negative breast cancers.
    Ward AK; Mellor P; Smith SE; Kendall S; Just NA; Vizeacoumar FS; Sarker S; Phillips Z; Alvi R; Saxena A; Vizeacoumar FJ; Carlsen SA; Anderson DH
    Breast Cancer Res; 2016 Jan; 18(1):12. PubMed ID: 26810754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development.
    Ortega-Molina A; Boss IW; Canela A; Pan H; Jiang Y; Zhao C; Jiang M; Hu D; Agirre X; Niesvizky I; Lee JE; Chen HT; Ennishi D; Scott DW; Mottok A; Hother C; Liu S; Cao XJ; Tam W; Shaknovich R; Garcia BA; Gascoyne RD; Ge K; Shilatifard A; Elemento O; Nussenzweig A; Melnick AM; Wendel HG
    Nat Med; 2015 Oct; 21(10):1199-208. PubMed ID: 26366710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KMT2D maintains neoplastic cell proliferation and global histone H3 lysine 4 monomethylation.
    Guo C; Chen LH; Huang Y; Chang CC; Wang P; Pirozzi CJ; Qin X; Bao X; Greer PK; McLendon RE; Yan H; Keir ST; Bigner DD; He Y
    Oncotarget; 2013 Nov; 4(11):2144-53. PubMed ID: 24240169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of KMT2D induces prostate cancer ROS-mediated DNA damage by suppressing the enhancer activity and DNA binding of antioxidant transcription factor FOXO3.
    Lv S; Wen H; Shan X; Li J; Wu Y; Yu X; Huang W; Wei Q
    Epigenetics; 2019 Dec; 14(12):1194-1208. PubMed ID: 31232159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cancer COMPASS: navigating the functions of MLL complexes in cancer.
    Ford DJ; Dingwall AK
    Cancer Genet; 2015 May; 208(5):178-91. PubMed ID: 25794446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KMT2D Deficiency Impairs Super-Enhancers to Confer a Glycolytic Vulnerability in Lung Cancer.
    Alam H; Tang M; Maitituoheti M; Dhar SS; Kumar M; Han CY; Ambati CR; Amin SB; Gu B; Chen TY; Lin YH; Chen J; Muller FL; Putluri N; Flores ER; DeMayo FJ; Baseler L; Rai K; Lee MG
    Cancer Cell; 2020 Apr; 37(4):599-617.e7. PubMed ID: 32243837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrated Analysis of Genetic Abnormalities of the Histone Lysine Methyltransferases in Prostate Cancer.
    Zhang Y; Yan L; Yao W; Chen K; Xu H; Ye Z
    Med Sci Monit; 2019 Jan; 25():193-239. PubMed ID: 30616239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone modifier gene mutations in peripheral T-cell lymphoma not otherwise specified.
    Ji MM; Huang YH; Huang JY; Wang ZF; Fu D; Liu H; Liu F; Leboeuf C; Wang L; Ye J; Lu YM; Janin A; Cheng S; Zhao WL
    Haematologica; 2018 Apr; 103(4):679-687. PubMed ID: 29305415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.